Next Generation News and Research

RSS

Oncos Therapeutics completes € 4 million investment from HealthCap

Oncos Therapeutics, a biotech company developing new cancer therapeutics based on its next generation oncolytic viruses, completed a € 4 million ($ 5.5 million) investment from HealthCap. With committed capital exceeding € 800 million, HealthCap is one of the largest specialized providers of venture capital within life sciences in Europe.

12 May 2010

LifeCodexx AG develops test using Next Generation Sequencing technologies for prenatal diagnostics

LifeCodexx AG has started operational research and development work on clinically validated diagnostic tests by using Next Generation Sequencing technologies. The work currently focuses on the field of prenatal diagnostics.

12 May 2010

Genmab reports revenues of DKK 107M for first-quarter 2010

Genmab's revenues were DKK 107 million (USD 19 million) for the first quarter of 2010. In the same period of 2009, Genmab recognized revenues of DKK 250 million (USD 45 million).

12 May 2010

Viking Systems to demonstrate 3DHD Vision System prototype at Hospital Build Asia 2010

Viking Systems, Inc. today announced that a prototype version of its Next Generation 3DHD Vision System will be demonstrated with Sony's prototype 3DHD Medical Display in Sony's booth at Hospital Build Asia 2010 which will run May 11 -13 in Singapore.

11 May 2010

Transition Therapeutics reports increased revenue in third-quarter 2010

Transition Therapeutics Inc., a product-focused biopharmaceutical company developing therapeutics for disease indications with large markets, today announced its financial results for the quarter ended March 31, 2010.

11 May 2010

Enzon reports income from continuing operations of $20.8M for first-quarter 2010

Enzon Pharmaceuticals, Inc. today announced its financial results for the first quarter of 2010. During the quarter, the Company completed the sale of its specialty pharmaceutical business. This transaction has now transformed the Company, both financially and operationally, into a biopharmaceutical company dedicated to the discovery and development of oncology medicines.

10 May 2010

Ardea Biosciences reports lower net loss of $10.1M for first-quarter 2010

Ardea Biosciences, Inc. a biotechnology company focused on the development of small-molecule therapeutics for the treatment of gout, cancer and human immunodeficiency virus (HIV), reported recent accomplishments and financial results for the first quarter ended March 31, 2010.

7 May 2010

Curis reports net income of $4.8M for first-quarter 2010

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today reported its financial results for the first quarter ended March 31, 2010.

6 May 2010

Latest LLMDA technology available to detect viruses, bacteria

Law enforcement authorities seeking to detect bioterrorism attacks, doctors diagnosing diseases and regulatory agencies checking product safety may find a new ally in a Lawrence Livermore National Laboratory detection technology.

6 May 2010

Viking Systems' first-quarter 2010 sales up 26%

Viking Systems, Inc. today announced financial results for its first quarter ended March 31, 2010. The Company reported a 26% increase in sales to $1,915,073 for the quarter ended March 31, 2010 and a net loss of $295,450 or ($0.01) per share.

5 May 2010

Micromet reports total revenues of $6.3 million for first-quarter 2010

Micromet, Inc., a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced its financial results for the first quarter ended March 31, 2010.

5 May 2010

BioClinica reports service revenues of $14,746,000 for first-quarter 2010

BioClinica, Inc., a global provider of clinical trial management services, today announced its financial results for the first quarter ended March 31, 2010.

From Clario 5 May 2010

Researchers receive NIDDK grant to identify pre-diabetes symptoms

A Biodesign team of researchers, led by Randall Nelson, PhD, has received a new five-year, $3.1 million award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of the National Institutes of Health. Their goal is to discover and validate telltale molecular signs to learn how to predict who will develop the disease long before any symptoms of diabetes appear.

5 May 2010

Iowa State University researcher works on faster method to detect salmonella from contaminated foods

Using technology available through a local company, an Iowa State University researcher is working on a faster method to detect and genetically identify salmonella from contaminated foods.

5 May 2010

Shorter shifts for endoscopists positively influence polyp detection rates

A shorter daily shift schedule for endoscopists, the physicians who perform colonoscopies, avoids a decrease in the polyp detection rate as the day progresses, research from Mayo Clinic indicates. The findings, which have implications for endoscopist scheduling, were presented by Mayo Clinic investigators today at Digestive Disease Week 2010, (http://www.ddw.org/wmspage.cfm?parm1=679) the annual meeting of the American Gastroenterological Association.

4 May 2010

DOE Argonne National Laboratory to upgrade to Advanced Photon Source

Advances in energy conservation, better materials for frontier technologies and new economic engines, and breakthroughs in understanding diseases: These are just a few of the potential discoveries, both basic and applied, to be enabled by an upgrade to the Advanced Photon Source (APS) at the U.S. Department of Energy's (DOE) Argonne National Laboratory. DOE today announced formal approval for conceptual design of the APS upgrade, the first in a series of major milestones that the project must meet under DOE's project management regimen.

4 May 2010

Rush Center for Urban Health Equity to focus on disparities in heart and lung disease

Rush University Medical Center has been awarded a $10 million grant from the National Institutes of Health to establish the Rush Center for Urban Health Equity. The aim of the Center is to find ways to promote changes to eliminate the disparities in heart and lung disease affecting inner city residents, in particular those who are low-income persons of color.

4 May 2010

Curis completes enrollment in Phase I clinical trial of CUDC-101 HDAC, EGFR and HER2 inhibitor

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that it has successfully completed enrollment and treatment of the last patient in its Phase I clinical trial of CUDC-101, Curis' first-in-class HDAC, EGFR and HER2 inhibitor.

3 May 2010

AppDynamics closes Series B financing round, raises $11 million

AppDynamics, Inc.™, the next-generation Application Performance Management (APM) company, today announced that it has closed its Series B round of financing, and had raised $11 million. The round is co-led by existing Series A investors Lightspeed Venture Partners and Greylock Partners, and will support the company's continued expansion as it takes advantage of market demand for next-generation application performance management (APM). To date, the company has received $16.5 million in venture funding.

3 May 2010

MicroCHIPS receives 2010 Edison Best New Product Award for Illume System

MicroCHIPS, Inc., a developer of intelligent implant systems, today announced that it has received a 2010 Edison Best New Product Award for its Illume product. The product was awarded Gold in the Science and Medical Category, recognizing the benefit that it will bring to millions of people with diabetes who must manage their blood sugar intensively to stay healthy.

30 Apr 2010